Clinical Trials Finder
Independent ClinicalTrials.gov directory
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

ClinicalTrials.gov ID: NCT06561386

Public ClinicalTrials.gov record NCT06561386. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced May 4, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

Study identification

NCT ID
NCT06561386
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
1,000 participants

Conditions and interventions

Interventions

  • Carboplatin Drug
  • Cisplatin Drug
  • Nivolumab Drug
  • Pembrolizumab Drug
  • Pemetrexed Drug
  • Relatlimab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 6, 2024
Primary completion
Jul 29, 2030
Completion
Aug 3, 2032
Last update posted
Apr 29, 2026

2024 – 2032

United States locations

U.S. sites
40
U.S. states
20
U.S. cities
40
Facility City State ZIP Site status
Local Institution - 0487 Mobile Alabama 36604 Not yet recruiting
Southern Arizona VA Health Care System Tucson Arizona 85723 Recruiting
Local Institution - 0112 Los Angeles California 90404 Withdrawn
University of California Davis (UC Davis) Comprehensive Cancer Center Sacramento California 95817 Recruiting
San Francisco Oncology Associates San Francisco California 94115 Recruiting
UCLA Hematology/Oncology - Santa Monica Santa Monica California 90404 Recruiting
Local Institution - 0472 Westminster Colorado 80023 Not yet recruiting
University of Miami Hospital and Clinics, Sylvester Cancer Center Miami Florida 33136 Recruiting
Memorial Hospital West Pembroke Pines Florida 33028 Recruiting
Florida Cancer Specialists - North St. Petersburg Florida 33705 Recruiting
Local Institution - 0477 Tamarac Florida 33321 Not yet recruiting
Florida Cancer Specialists - East West Palm Beach Florida 33401 Recruiting
Affiliated Oncologists, LLC Chicago Ridge Illinois 60415 Recruiting
Cancer Center of Kansas Wichita Kansas 67214 Recruiting
Saint Elizabeth Medical Center Edgewood Edgewood Kentucky 41017 Recruiting
Baptist Health Lexington Lexington Kentucky 40503 Recruiting
Local Institution - 0473 Royal Oak Michigan 48073 Not yet recruiting
Hattiesburg Clinic Hematology/Oncology Hattiesburg Mississippi 39401-7233 Recruiting
Local Institution - 0308 Bozeman Montana 59715 Completed
Renown Regional Medical Center Reno Nevada 89502 Recruiting
Local Institution - 0346 Paterson New Jersey 07503 Completed
Local Institution - 0381 Albuquerque New Mexico 87108 Completed
Local Institution - 0356 Hawthorne New York 10532 Active, not recruiting
Veterans Affairs New York Harbor Healthcare System New York New York 10016 Recruiting
Local Institution - 0380 Northport New York 11768 Withdrawn
University of Rochester Medical Center Rochester New York 14642 Recruiting
SUNY Upstate Medical University Syracuse New York 13210 Recruiting
Local Institution - 0357 The Bronx New York 10468 Withdrawn
Local Institution - 0352 Asheville North Carolina 28806 Completed
East Carolina University Greenville North Carolina 27858 Recruiting
Local Institution - 0369 Canton Ohio 44708 Withdrawn
University of Cincinnati Medical Center Cincinnati Ohio 45219 Recruiting
Local Institution - 0199 Cleveland Ohio 44106 Completed
Local Institution - 0366 Massillon Ohio 44646 Withdrawn
Lancaster General Hospital - Ann B Barshinger Cancer Institute Lancaster Pennsylvania 17601 Recruiting
Texas Oncology - West Texas Abilene Texas 79606 Recruiting
Local Institution - 0305 Harlingen Texas 78550 Withdrawn
University of Texas MD Anderson Cancer Center Houston Texas 77030 Recruiting
The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center Tyler Texas 75701 Recruiting
Local Institution - 0302 Salt Lake City Utah 84112 Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 258 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06561386, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 29, 2026 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06561386 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →